05:08 PM EDT, 06/16/2025 (MT Newswires) -- Castle Biosciences ( CSTL ) entered into a collaboration and license agreement with SciBase Holding to develop diagnostic tests that predict flare-ups in patients with atopic dermatitis

Under the agreement, the companies will also explore additional clinical applications for dermatologic diseases, using SciBase's Electrical Impedance Spectroscopy technology, Castle Biosciences ( CSTL ) said Monday in a statement.

Upon achieving development milestones, SciBase will receive a single-digit royalty percentage on Castle's gross margin, along with a low double-digit percentage mark-up on product sales to Castle, according to the statement.

SciBase will also receive a milestone payment of $5 million when Castle reaches $50 million in annual sales.

Castle's initial territory in the collaboration will be North America, while SciBase's will include the EU, Switzerland, the United Arab Emirates, Japan and South Korea.